Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

NIH × Neoplasms × ARQ 197 × Clear all

Phase

Status

Sponsor Class

INDUSTRY 8 NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Triple Negative Breast Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Solitary Fibrous Tumor, Pleural 1 Solid Neoplasm 1 Sarcoma 1 Renal Insufficiency 1 Paraproteinemias 1 Osteolysis 1 Neoplasms 1 Multiple Myeloma 1 Mesothelioma, Malignant 1 Hypercalcemia 1 Hematologic Neoplasms 1 Fractures, Spontaneous 1 Childhood Solid Neoplasm 1 Carcinoma, Renal Cell 1 Breast Neoplasms 1 Bone Diseases, Metabolic 1 Anemia 1 Amyloidosis 1 Adult Solid Neoplasm 1

Interventions

Cyclophosphamide 13 Bevacizumab 9 Interleukin-2 8 aldesleukin 7 fludarabine 6 fludarabine phosphate 5 Gemcitabine 5 Filgrastim 5 sargramostim 4 Vincristine 4 Trastuzumab 4 Thalidomide 4 Radiotherapy 4 Prednisone 4 Paclitaxel 4 Leucovorin 4 Bortezomib 4 Biopsy 4 veliparib 3 vandetanib 3 tariquidar 3 pazopanib 3 montanide ISA 51 3 Topotecan 3 Sorafenib 3 Sirolimus 3 Oxaliplatin 3 Melphalan 3 MART-1 Antigen 3 Fluorouracil 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01468922 2022-07-01

Pazopanib and ARQ 197 for Advanced Solid Tumors

National Institutes of Health Clinical Center (CC)

Phase 1 Completed

32 enrolled 21 charts

Neoplasms, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡